Accelerating patient access to oncology medicines with multiple indications in Europe
Background: In recent years, innovation in oncology has created new challenges for pricing and reimbursement systems. Oncology medicines with multiple indications face a number of access challenges: (1) the number of assessments and administrative burden; (2) aligning price to different values of th...
Saved in:
Main Authors: | R. Lawlor (Author), T. Wilsdon (Author), E. Darquennes (Author), D. Hemelsoet (Author), J. Huismans (Author), R. Normand (Author), A. Roediger (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Why is the screening rate in lung cancer still low? A seven-country analysis of the factors affecting adoption
by: Charlotte Poon, et al.
Published: (2023) -
Cardiovascular medicine prices as an indicator of access to medicines and their rational use
by: C M. Razzakova, et al.
Published: (2019) -
Are Turkish pharmaceutical pricing strategies an access barrier to oncology medicines for Türkiye?
by: Elif Hilal Vural, et al.
Published: (2024) -
Accelerating the 5G transition in Europe How to boost investments in transformative 5G solutions
by: Gilles, François
Published: (2021) -
The need to accelerate access to new drugs for multidrug-resistant tuberculosis
by: Helen S Cox, et al.
Published: (2015)